Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.71 |
| ▸ | RET | P07949 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16823312 | 0.97 | EGFR (0.70) | EGFRRETKDRABCB1MAPT | |
| SCHEMBL431393 | 0.96 | EGFR (0.69) | EGFRRETKDRSIGMAR1BCHE | |
| SCHEMBL12678185 | 0.87 | EGFR (0.80) | EGFRRETKDRABCB1MAPT | |
| SCHEMBL12792587 | 0.85 | EGFR (0.72) | EGFRRETKDRABCB1MAPT | |
| SCHEMBL28031602 | 0.84 | EGFR (0.74) | EGFRRETKDRABCB1MAPT | |
| SCHEMBL13186952 | 0.83 | EGFR (0.69) | EGFRRETKDRABCB1MAPT | |
| SCHEMBL7548426 | 0.83 | MAOA (0.60) | ABCB1MAPTSIGMAR1CYP3A4CYP2C9 | |
| SCHEMBL7375795 | 0.82 | POLH (0.61) | EGFRRETKDRABCB1MAPT | |
| SCHEMBL24882669 | 0.81 | EGFR (0.78) | EGFRRETKDRABCB1MAPT | |
| SCHEMBL974548 | 0.81 | MAPT (1.00) | EGFRRETKDRABCB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642854-B2 | Flavanoid compounds and process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-05-09 | — | — | US | disclosed |
| US-20150174135-A1 | FLAVANOID COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2015-06-25 | — | — | US | disclosed |
| US-8969384-B2 | Flavonoid compounds and process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-03-03 | — | — | US | disclosed |
| US-20120022062-A1 | Flavanoid Compounds and Process for Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-01-26 | — | — | US | disclosed |
| US-20110059913-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2011-03-10 | — | — | US | disclosed |
| US-20110059913-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2011-03-10 | — | — | US | disclosed |
| US-20110059913-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2011-03-10 | — | — | US | disclosed |
| US-7855200-B2 | Method for treatment of gastric ulcers and ulcers induced by aspirin | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-12-21 | — | — | US | disclosed |
| US-7855200-B2 | Method for treatment of gastric ulcers and ulcers induced by aspirin | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-12-21 | — | — | US | disclosed |
| US-7855200-B2 | Method for treatment of gastric ulcers and ulcers induced by aspirin | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-12-21 | — | — | US | disclosed |
| EP-1976508-A2 | FLAVONOIDS ISOLATED FROM OROXYLUM INDICUM FOR TREATMENT OF GASTROINTESTINAL TOXICITY, ASSOCIATED SYMPTOMS AND ULCERS | Council of Scientific and Industrial Research (IN) | 2008-10-08 | — | — | EP | disclosed |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-13 | — | — | US | disclosed |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-13 | — | — | US | disclosed |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-13 | — | — | US | disclosed |
| WO-2007080484-A2 | FLAVONOIDS ISOLATED FROM OROXYLUM INDICUM FOR TREATMENT OF GASTROINTESTINAL TOXICITY, ASSOCIATED SYMPTOMS AND ULCERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174135-A1 | FLAVANOID COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | F2, FOXM1, HRH2 | EGFR 3521/4885RET 2552/4885KDR 4551/4885 |
| US-20110059913-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS | MLN, FABP6, SI | EGFR 1564/4885RET 3400/4885KDR 3142/4885 |
| US-20120022062-A1 | Flavanoid Compounds and Process for Preparation Thereof | F2, FOXM1, HRH2 | EGFR 3521/4885RET 2552/4885KDR 4551/4885 |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | FABP6, MLN, SI | EGFR 1369/4885RET 3556/4885KDR 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.